States cannot yet order children's COVID-19 vaccines through the federal Vaccines for Children program because the CDC has not opened ordering for them, according to a Wall Street Journal report that put a logistical deadline at the center of the country's vaccine-policy fight. The program supplies free vaccines to about half of American children, those who are uninsured, underinsured, Medicaid-eligible, or American Indian and Alaska Native. Commercially insured families can already get shots at retail pharmacies. The children the program serves cannot, at least not through it.
The mechanism is simple and the stakes are not. States place orders through the program once the federal government signs off, and the federal sign-off has not come. A Department of Health and Human Services spokesperson told the Journal that COVID-19 "does not follow the same predictable seasonal pattern as influenza" and that an arbitrary September date should not be treated as a deadline for vaccine procurement. The CDC said it is finalizing decisions on procurement through the program and through the Section 317 program, which covers adults without other access. Finalizing is not the same as opening.
How the program is supposed to work
Vaccines for Children is one of the quiet successes of American public health. Since 1994 it has been the reason a child's vaccine status in most of the country does not depend on a parent's insurance card. Pediatricians and clinics enroll, order through the state, and vaccinate children who would otherwise go without. The program operates on a rhythm: commercial vaccine availability lands first, then federal ordering opens, usually within a couple of weeks, and doses flow to the states.
That rhythm is what the delay has broken. The commercial doses are on pharmacy shelves now. The program's ordering window has not opened, which means the children who rely on the program are waiting on the federal decision rather than the vaccine supply. The pattern inverts the usual access problem: this time the doses exist and the paperwork does not.
The federal government's position is that the seasonal-pattern argument justifies the pace, and there is a real medical question buried in it. COVID-19 has not settled into the predictable fall-to-spring rhythm of influenza, and vaccine policy built on a strict September procurement deadline does not fit the epidemiology. But the children waiting for the program's doses are not waiting on epidemiology. They are waiting on an administrative decision, and the administration has not said when it will come.
The policy fight behind the logistics
The delay is the visible edge of a longer policy fight. The CDC no longer recommends COVID vaccination for all children, instead telling parents to consult their doctors, a shift from the previous recommendation covering everyone six months and older. A federal judge blocked the administration from enacting a narrower vaccine schedule earlier this year, and the health secretary has pushed to broadly step back from vaccine recommendations. The children's program is caught in the middle: its ordering process runs through the same agencies whose guidance has been the subject of the fight.
The 2025 version of this delay had a specific cause: recommendations from the CDC's advisory committee on immunization practices that were not signed off by the health secretary or his deputy, leaving states unable to order doses, plus a legal dispute over the committee's membership after a judge ruled some Kennedy-appointed members were not qualified. This year's delay has not been attributed to the same sign-off gap, at least not publicly. The effect on the ground is similar.
Demand has fallen sharply, which is the honest context for how much this matters. Fewer than 10 percent of children aged six months to seventeen received a COVID vaccine last year, according to CDC data. The program's delay affects a smaller number of families than it would have in 2021. But the families it affects are the ones with the fewest alternatives: a child on Medicaid cannot simply pay for the pharmacy dose, and the community clinics that serve uninsured families order through the program or not at all.
The program that turned vaccination into infrastructure
Vaccines for Children has been running since 1994, created in the wake of a measles outbreak that exposed what happens when vaccine access follows insurance status. The program buys vaccines at federal prices and distributes them through state health departments to enrolled providers, who vaccinate children at no cost to families. It has become the backbone of childhood vaccination in the United States, covering roughly half of all children and a majority of childhood vaccine doses in many states.
The program's design is why the ordering delay has the shape it does. States do not hold large vaccine inventories; they order against the federal contract as doses are needed, and the ordering window opens when the federal government says it opens. The program runs on that federal decision point, which is small and administrative and sits at the top of a pipeline that ends in a community clinic in a rural county. When the decision point is late, everything downstream is late by the same amount.
The program also carries the country's equity argument in its structure. The children it serves, uninsured, Medicaid-eligible, and American Indian and Alaska Native, are exactly the children whose families cannot absorb a pharmacy cash price or a travel burden. The program exists so their vaccine status does not depend on those things. A delay in the program is therefore not evenly distributed: the children who can pay are vaccinated, and the children the program exists for wait.
What states did the last time this happened
During the 2025 delay, states improvised. Some issued standing orders, some used executive orders, some passed legislation to keep their own procurement moving without the federal sign-off. The improvisations worked unevenly, and they revealed the real cost of the delay: not the vaccines themselves, which existed, but the uncertainty forced onto clinics, parents, and state health departments about whether and when the federal pipeline would open.
The same improvisation is visible again. States that can afford to front their own procurement are doing so. States that cannot are waiting on the federal decision, and the waiting is the harm. A clinic that does not know when it can order cannot schedule vaccination days, cannot notify families, and cannot plan its own vaccine-storage and staffing needs. The delay compounds as it runs, because every week of uncertainty becomes a week of missed appointments that will not all be rescheduled.
The administration's argument, that COVID does not follow influenza's seasonal calendar and an arbitrary September deadline should not govern procurement, is a real epidemiological point. But the program's logistics do not run on epidemiology. They run on decision dates, and the absence of a decision date has its own consequence: the federal government has chosen not to set a deadline, and the states, the clinics, and the families are living with the open-endedness. A government that declines an arbitrary date is also a government that has not provided a real one, and in vaccine procurement, an open question is a cost.
For families, the practical guidance is unglamorous and important. A child covered by the program cannot simply pay the pharmacy's cash price, and a parent should not be told to. The right answer, for now, is the pediatrician's office and the community clinic, which can say plainly whether the program's doses have arrived for them and schedule accordingly when they do. Parents with commercial insurance face no barrier and can use the pharmacies that already have doses. The two-tier arrangement is exactly what the program was built to prevent, and it is what the delay has temporarily restored. The restoration is administrative, not medical, and it will end the day the federal government opens the ordering window it has not yet opened.
Who feels the delay first
The delay lands unevenly by design. Commercial pharmacies have had shots for weeks. Pediatric practices serving mostly insured families can order through commercial channels. The wait concentrates in community health centers, rural clinics, and the safety-net systems that serve the program's population, the same institutions that public health officials spent years warning were the most strained.
Some states have responded with standing orders and their own procurement measures, the same improvisations they used during earlier delays. The patchwork works where it exists. Where it does not, the practical effect is a child whose parent wants the vaccine, whose provider participates in the program, and whose dose has not been ordered because the federal process has not opened. That is not a supply failure or a demand failure. It is a timing failure, and timing failures in public health have a way of becoming equity failures, because the families who can wait are not the families who need the program.
The Department of Health and Human Services has said an arbitrary September date should not drive procurement. The states are not asking for an arbitrary date to drive medicine. They are asking for a date at which the ordering can start, so that the program that vaccinates half the country's children does not finish the season after the pharmacies do.
Primary sources
- Honolulu Star-Advertiser for the Wall Street Journal report, the HHS statement, and the program's role.
- Union Leader for the scope of the delay and the program details.
- Seattle Times for the earlier 2025 delay and its causes.